Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia
Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia
复制标题
小檗胺克服了伊马替尼引起的中性粒细胞减少症，并允许中国慢性粒细胞白血病慢性期患者出现细胞遗传学反应
DOI：
10.1007/s12185-011-0887-7
复制
发表时间：
2011-07
影响因子：
2.1
通讯作者：
Huang He
中科院分区：
文献类型：
--
作者：
Zhao Yanmin;Tan Yamin;Wu Gongqiang;Liu Lizhen;Wang Yingjia;Luo Yi;Shi Jimin;Huang He
在伊马替尼治疗过程中，许多慢性粒细胞白血病（CML）患者发生严重的中性粒细胞减少症，导致治疗中断，并可能影响对伊马替尼的反应。小檗胺（一种双苄基异喹啉生物碱）已在亚洲国家广泛用于治疗与化疗相关的白细胞减少症。为了研究小檗胺是否在逆转伊马替尼相关中性粒细胞减少方面显示临床益处，我们分析了63例慢性期CML患者，这些患者发生了≥2级中性粒细胞减少，并接受了小檗胺治疗（n= 34，小檗胺组）或未接受小檗胺治疗（n= 29，对照组）。在患有2级中性粒细胞减少症的患者中，13名患者中有5名（38.5%）在没有小檗胺支持的情况下进展为3级中性粒细胞减少症，而在小檗胺组中，该比率降至3/20（15%）（p= 0.213）。尽管两组从≥3级中性粒细胞减少症中恢复的比率相似（94.1 vs. 90.5%，p = 0.559），但小檗胺显著缩短了恢复时间（中位数11 vs. 24 d，p= 0.006），并防止了≥3级中性粒细胞减少症的复发（18.8 vs. 52.6%，p = 0.039）。此外，在小檗胺支持下，达到完全细胞遗传学缓解的时间显著缩短（中位数，6.5 vs. 10个月，p= 0.007）。没有与小檗胺治疗相关的严重不良事件。结论：本研究揭示了小檗胺治疗慢性粒细胞白血病伴伊马替尼诱导的中性粒细胞减少症的潜在临床价值。小檗胺的使用可能通过刺激正常造血和更快的中性粒细胞减少恢复来改善对伊马替尼的反应。
During imatinib therapy, many patients with chronic myeloid leukemia (CML) develop severe neutropenia, leading to treatment interruptions, and potentially compromising response to imatinib. Berbamine (a bisbenzylisoquinoline alkaloid) has been widely used in Asian countries for managing leukopenia associated with chemotherapy. To investigate whether berbamine shows clinical benefit in reversing imatinib-associated neutropenia, we analyzed 63 chronic-phase CML patients who had developed grade ≥2 neutropenia and were treated with (n= 34, berbamine group) or without (n= 29, control group) berbamine. Among those patients with grade 2 neutropenia, five of 13 (38.5%) progressed to grade 3 neutropenia without berbamine support, while in the berbamine group, the rate decreased to 3/20 (15%) (p= 0.213). Although the rate of recovery from grade ≥3 neutropenia was similar in the two groups (94.1 vs. 90.5%,p= 0.559), berbamine markedly shortened the recovery time (median, 11 vs. 24 days,p= 0.006), and prevented recurrence of grade ≥3 neutropenia (18.8 vs. 52.6%,p= 0.039). Moreover, with berbamine support, the time to achieve complete cytogenetic response was significantly shorter (median, 6.5 vs. 10 months,p= 0.007). There were no severe adverse events associated with berbamine treatment. In conclusion, the present study reveals the potential clinical value of berbamine in the treatment of CML with imatinib-induced neutropenia. The use of berbamine may improve response to imatinib by stimulating normal hematopoiesis and faster neutropenia recovery.
登录
查看更多内容
影响因子：
2.1
作者：
T. Nagai;J. Takeuchi;N. Dobashi;Y. Kanakura;S. Taniguchi;K. Ezaki;C. Nakaseko;A. Hiraoka;M. Okada;Y. Miyazaki;T. Motoji;M. Higashihara;N. Tsukamoto;H. Kiyoi;S. Nakao;K. Shinagawa;R. Ohno;T. Naoe;K. Ohnishi;N. Usui
通讯作者：
T. Nagai;J. Takeuchi;N. Dobashi;Y. Kanakura;S. Taniguchi;K. Ezaki;C. Nakaseko;A. Hiraoka;M. Okada;Y. Miyazaki;T. Motoji;M. Higashihara;N. Tsukamoto;H. Kiyoi;S. Nakao;K. Shinagawa;R. Ohno;T. Naoe;K. Ohnishi;N. Usui
影响因子：
158.5
作者：
Druker, Brian J.;Guilhot, Francois;Larson, Richard A.
通讯作者：
Larson, Richard A.
影响因子：
11.2
作者：
K. Shimoda;S. Okamura;N. Harada;Wataru Ikematsu;S. Kondo;C. Kawasaki;Takeshi I Anaka;Tetsuya Etou;Kouichi Akashi;Takashi Okamura;Tsunefumi Shibuya;Mine Harada;Yoshiyuki Niho;Y. Nj
通讯作者：
K. Shimoda;S. Okamura;N. Harada;Wataru Ikematsu;S. Kondo;C. Kawasaki;Takeshi I Anaka;Tetsuya Etou;Kouichi Akashi;Takashi Okamura;Tsunefumi Shibuya;Mine Harada;Yoshiyuki Niho;Y. Nj
影响因子：
11.4
作者：
Marin, D;Marktel, S;Apperley, JF
通讯作者：
Apperley, JF
影响因子：
10.1
作者：
D. Marin;S. Marktel;N. Foot;M. Bua;J. Goldman;J. Apperley
通讯作者：
D. Marin;S. Marktel;N. Foot;M. Bua;J. Goldman;J. Apperley